PL2694538T3 - Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5 - Google Patents

Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5

Info

Publication number
PL2694538T3
PL2694538T3 PL12713969T PL12713969T PL2694538T3 PL 2694538 T3 PL2694538 T3 PL 2694538T3 PL 12713969 T PL12713969 T PL 12713969T PL 12713969 T PL12713969 T PL 12713969T PL 2694538 T3 PL2694538 T3 PL 2694538T3
Authority
PL
Poland
Prior art keywords
anexin
therapeutic
compositions
prophylactic methods
prophylactic
Prior art date
Application number
PL12713969T
Other languages
English (en)
Inventor
Knut Pettersson
Original Assignee
Annexin Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexin Pharmaceuticals Ab filed Critical Annexin Pharmaceuticals Ab
Publication of PL2694538T3 publication Critical patent/PL2694538T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL12713969T 2011-04-05 2012-04-05 Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5 PL2694538T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472002P 2011-04-05 2011-04-05
US201161472013P 2011-04-05 2011-04-05

Publications (1)

Publication Number Publication Date
PL2694538T3 true PL2694538T3 (pl) 2017-04-28

Family

ID=45953134

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12713969T PL2694538T3 (pl) 2011-04-05 2012-04-05 Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5

Country Status (7)

Country Link
US (3) US20140037614A1 (pl)
EP (1) EP2694538B1 (pl)
DK (1) DK2694538T3 (pl)
ES (1) ES2607066T3 (pl)
HU (1) HUE030922T2 (pl)
PL (1) PL2694538T3 (pl)
WO (1) WO2012136819A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
JP2024515311A (ja) * 2021-04-25 2024-04-08 上海薩美細胞技術有限公司 肺損傷を治療するための薬物
US20240141001A1 (en) 2021-06-14 2024-05-02 Institut National de la Santé et de la Recherche Médicale Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
CA3189560A1 (en) * 2022-03-04 2023-09-04 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Methods of treating a traumatic brain injury
CN118490808A (zh) * 2023-02-15 2024-08-16 上海萨美细胞技术有限公司 一种用于治疗骨质疏松症的药物
CN118001375A (zh) * 2023-04-12 2024-05-10 上海萨美细胞技术有限公司 一种用于难愈性创面修复的药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067857A2 (en) 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
DK1755642T3 (da) 2004-04-15 2010-05-10 Athera Biotechnologies Ab Annexin V til forebyggelse af plaksprængning
ES2393163T3 (es) 2007-12-18 2012-12-19 Athera Biotechnologies Ab Compuestos y métodos para el tratamiento de enfermedad vascular
CN101969978A (zh) * 2008-02-22 2011-02-09 阿瑟拉生物技术公司 预防或治疗再狭窄的化合物和方法

Also Published As

Publication number Publication date
US20200179484A1 (en) 2020-06-11
HUE030922T2 (en) 2017-06-28
EP2694538B1 (en) 2016-09-14
ES2607066T3 (es) 2017-03-29
US20140037614A1 (en) 2014-02-06
EP2694538A1 (en) 2014-02-12
US20180015142A1 (en) 2018-01-18
DK2694538T3 (da) 2017-01-02
WO2012136819A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
PL2694538T3 (pl) Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
PL2672826T3 (pl) Kompozycje chwastobójcze zawierające topramezon, pinoksaden i klokwintocet
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
EP2763998A4 (en) TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF
EP2720539A4 (en) OPSIN BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE
IL250307A0 (en) Pesticide preparations and methods
ZA201308892B (en) Compositions and methods
EP2766183A4 (en) IRON FIBER COMPOSITION, PREPARATION THEREOF AND USES THEREOF
EP2672952A1 (en) Hair treatment compositions
EP2688576A4 (en) HEAT-EXTRACTED EPIPLOON EXTRACTS, COMPOSITIONS, PREPARATION METHODS AND USES THEREOF
AU2011901447A0 (en) Prophylactic and therapeutic compositions
AU2012903646A0 (en) Therapeutic methods and compositions
AU2012901350A0 (en) Therapeutic methods and compositions
AU2011903938A0 (en) Therapeutic methods and compositions
AU2011903217A0 (en) Immunogenic compositions and methods therefor
GB201116340D0 (en) Compositions and methods
GB201107454D0 (en) Compositions and uses
GB201101924D0 (en) Compositions and uses
GB201121663D0 (en) Process and compositions
AU2011902301A0 (en) Novel Formulation and Treatment Methods
GB201120470D0 (en) Compositions and uses thereof
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai